Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells

scientific article

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/JPET.108.147306
P698PubMed publication ID19258520
P5875ResearchGate publication ID24174811

P50authorMichele T. Yip-SchneiderQ40125820
P2093author name stringC Max Schmidt
Sabrina C Wentz
Patrick J Klein
Alex Menze
Amer Zeni
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)1063-1070
P577publication date2009-03-03
P1433published inJournal of Pharmacology and Experimental TherapeuticsQ1500272
P1476titleResistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells
P478volume329

Reverse relations

cites work (P2860)
Q37977357Autoregulation of kinase dephosphorylation by ATP binding in AGC protein kinases.
Q39852061Cardiotrophin-1 maintains the undifferentiated state in skeletal myoblasts.
Q33789572Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.
Q42849220Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1/2 and AKT signaling pathways.
Q42261463Disrupting CCT-β : β-tubulin selectively kills CCT-β overexpressed cancer cells through MAPKs activation.
Q34687273ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells
Q35894374Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.
Q28485293Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines
Q41898874Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA
Q39612071Hepatitis B virus regulates Raf1 expression in HepG2.2.15 cells by enhancing its promoter activity
Q39229719Hepatitis B virus regulation of Raf1 promoter activity through activation of transcription factor AP-2α
Q39500664Inhibition of doxorubicin‐induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib – the role of extracellular signal‐regulated kinase counteraction
Q36241772Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.
Q37828536Novel mitogen-activated protein kinase kinase inhibitors
Q33945648PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells
Q28542662Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines
Q35558850Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity.
Q43180945Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems
Q38788201The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition.
Q84089408Uncaging Akt
Q53257577p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma

Search more.